Author Correction: Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
Panagiotis Ntziachristos, Aristotelis Tsirigos, G. Grant Welstead, Thomas Trimarchi et autres
0 citationsNature
Age UK
London · GB · nonprofit
4095Publications signalées
388394Citations signalées
12Thèmes principaux
Principaux domaines
Asthma and respiratory diseasesProtein Degradation and InhibitorsMonoclonal and Polyclonal Antibodies ResearchComputational Drug Discovery MethodsMultiple Myeloma Research and TreatmentsChronic Obstructive Pulmonary Disease (COPD) ResearchDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsSystemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and TherapiesChemical Synthesis and AnalysisImmune Cell Function and Interaction
Évolution annuelle
Publications récentes
Challenges and Insights from the Mepolizumab Pregnancy Exposure Study
Keele Wurst, Michael Schatz, Subramanya Kumar, Megan Delgado et autres
0 citationsDrug Safety
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma
Sagar Lonial, P RICHARDSON, Geraldine Ferron‐Brady, Fernando Carreño et autres
0 citationsHaematologica
P31-09 Target to Medicine: A Strategy for Managing the Risk of Mitochondrial Toxicity
J. Lyon, J. Armitage, D. Grimsditch, Z. Spencer et autres
0 citationsToxicology Letters
OS03-05 De-Risking ADCs: In Vitro Detection of Off-Target Lung Liabilities Using High-Content Imaging
E. Hoffman, J. Joel, E. Zeqiri, R. Mahendran et autres
0 citationsToxicology Letters
P18-29 In vitro assessment of on-target off-tumour activity of a T cell engager
L. Thompson, P. Allen, G. Sohanpal, D. Harte et autres
0 citationsToxicology Letters
S29-02 Case-studies: Comparing NA mutagenesis and carcinogenesis potency and potentially using in vivo mutagenicity for risk assessment
A. Lynch, J. Wills, J. Howe, J. Harvey
0 citationsToxicology Letters
S24-04 Leveraging New Approach Methodologies (NAMs) for Non-Oncology Therapeutics: Case Studies in Safety De-risking and Regulatory Outcomes
0 citationsToxicology Letters
Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas J. Williams et autres
0 citationsBiotechnology and Bioengineering
A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors
Lillian L. Siu, Omid Hamid, Reva Schneider, Jordi Rodón et autres
0 citationsClinical Cancer Research
NLRX1 is an essential, druggable regulator of mitochondrial permeability transition
Rachel Peltier-Heap, David W. Frederick, Robert J. Pickering, Sonja Ghidelli‐Disse et autres
0 citationsbioRxiv (Cold Spring Harbor Laboratory)
Brachyury expression levels predict lineage potential and axis-forming ability of in vitro-derived neuromesodermal progenitors
Anahí Binagui-Casas, Anna Granés, Alberto S. Ceccarelli, Matthew French et autres
3 citationsPLoS Biology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.